welcome
Working for the people to improve healthcare

CIBBIM-Nanomedicine Director

Dr. Simó Schwartz Jr


Nanomedicine and Advanced Therapies as translational sciences have the ultimate goal to provide cost effective novel therapies and diagnostics. As key enable technologies these new options will cause profound changes in healthcare, making feasible more personalized, predictive, preventive, and regenerative medicine.

PRECLINICAL SERVICES

This platform offers standard in vitro experimentation procedures for the functional validation of candidate genes and biomarkers, and for the efficacy and toxicological evaluation of new drugs, biomaterials and biomarkers.
Read more

At the moment, the platform offers standardin vivo experimentation procedures for the evaluation of new therapeutic targets, nanotherapies and biomarkers in the field of oncology and rare diseases.
Read more

Latest
news

News

Vall d’Hebron organizes a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease

Vall d’Hebron organizes a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease

Next Monday, November 19, Vall d’Hebron will hold a seminar focused on Lysosomal Rare Disorders: Focus on Fabry Disease. The seminar is part of the Rare...

Read more
VHIR researchers receive European funding for liver disease research

VHIR researchers receive European funding for liver disease research

Dr. Joan Genescà, head of the Liver Diseases research group and Dr. María Martell, group researcher and head of the Advanced Liver Disease laboratory, from the Liver...

Read more
Nanomedicine & Bioengineering

Publications

Extracellular HMGA1 promotes tumor Invasion and Metastasis in Triple-Negative Breast Cancer.

Mendez O, Peg V, Salvans C, Pujals M, Fernandez Y, Abasolo I, Perez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S, Ramon Y Cajal S, Tabernero J, Cortes...

Read more